Table 1.
Baseline characteristics of the study population
| Parameters | Total (n = 36) |
|---|---|
| Age, years (median, IQR) | 59 (53.25–64.25) |
| ≥ 60 | 16 [44.4%] |
| < 60 | 20 [55.6%] |
| Sex, n [%] | |
| Female | 15 [41.7] |
| Male | 21 [58.3] |
| ECOG performance, n [%] | |
| 0 | 20 [55.6] |
| 1 | 13 [36.1] |
| 2 | 3 [8.3] |
| Child–Pugh score, n [%] | |
| A | 27 [75] |
| B* | 9 [25] |
| CA19-9, U/mL (median, IQR) | 107.1 (21.6–421.5) |
| ≥ 200 | 21 [58.3] |
| < 200 | 15 [41.7] |
| HBV infection, n [%] | 4 [11.1] |
| Differentiated histology, n [%] | |
| Poor | 16 [44.4] |
| Moderate | 13 [36.1] |
| Well | 7 [19.0] |
| TNM stage, n [%] | |
| III | 8 [22.2] |
| IV | 28 [77.8] |
| Site of metastases, n [%] | |
| Liver | 28 [77.8] |
| Direct invasion | 5 [13.8] |
| Intrahepatic | 23 [68.9] |
| Lymph nodes | 30 [83.3] |
| Lung | 6 [16.7] |
| Bone | 4 [11.1] |
| Others | 4 [11.1] |
| PD-L1 expression, n [%] | |
| Positive | 12 [33.3] |
| Negative | 24 [66.7] |
| Previous treatment regimens, n [%] | |
| Systemic chemotherapy | |
| Capecitabine | 14 [38.9] |
| Gemcitabine + capecitabine | 9 [25] |
| Gemcitabine + cisplatin | 5 [13.9] |
| Gemcitabine + S-1 | 2 [5.6] |
| Durvalumab + gemcitabine + cisplatin | 2 [5.6] |
| Pembrolizumab + gemcitabine + cisplatin | 4 [11.1] |
| Targeted therapy | |
| Lenvatinb | 9 [25] |
| Transarterial chemoembolization | 6 [16.7] |
| Radical surgery resection | 30 [83.3] |
| Palliative surgical resection | 6 [16.7] |
| Regional radiotherapy or ablation | 8 [22.2] |
| Type of anti-PD-1 antibodies, n [%] | |
| Toripalimab | 17 [47.2] |
| Pembrolizumab | 13 [36.1] |
| Tislelizumab | 6 [16.7] |
| Parameters | Total (n = 36) |
|---|---|
| Age, years (median, IQR) | 59 (53.25–64.25) |
| ≥ 60 | 16 [44.4%] |
| < 60 | 20 [55.6%] |
| Sex, n [%] | |
| Female | 15 [41.7] |
| Male | 21 [58.3] |
| ECOG performance, n [%] | |
| 0 | 20 [55.6] |
| 1 | 13 [36.1] |
| 2 | 3 [8.3] |
| Child–Pugh score, n [%] | |
| A | 27 [75] |
| B* | 9 [25] |
| CA19-9, U/mL (median, IQR) | 107.1 (21.6–421.5) |
| ≥ 200 | 21 [58.3] |
| < 200 | 15 [41.7] |
| NLR, (median, IQR) | 3.3 (2.2–7.4) |
| ≥ 5.57 | 12 [33.3] |
| < 5.57 | 21 [58.3] |
| NA | 3 [8.3] |
| HBV infection, n [%] | 4 [11.1] |
| Differentiated histology, n [%] | |
| Poor | 16 [44.4] |
| Moderate | 13 [36.1] |
| Well | 7 [19.0] |
| TNM stage, n [%] | |
| III | 8 [22.2] |
| IV | 28 [77.8] |
| Site of metastases, n [%] | |
| Liver | 28 [77.8] |
| Direct invasion | 5 [13.8] |
| Intrahepatic | 23 [68.9] |
| Lymph nodes | 30 [83.3] |
| Lung | 6 [16.7] |
| Bone | 4 [11.1] |
| Others | 4 [11.1] |
| PD-L1 expression, n [%] | |
| Positive | 12 [33.3] |
| Negative | 24 [66.7] |
| Previous treatment regimens, n [%] | |
| Systemic chemotherapy | |
| Capecitabine | 14 [38.9] |
| Gemcitabine + capecitabine | 9 [25] |
| Gemcitabine + cisplatin | 5 [13.9] |
| Gemcitabine + S-1 | 2 [5.6] |
| Durvalumab + gemcitabine + cisplatin | 2 [5.6] |
| Pembrolizumab + gemcitabine + cisplatin | 4 [11.1] |
| Targeted therapy | |
| Lenvatinb | 9 [25] |
| Transarterial chemoembolization | 6 [16.7] |
| Radical surgery resection | 30 [83.3] |
| Palliative surgical resection | 6 [16.7] |
| Regional radiotherapy or ablation | 8 [22.2] |
| Type of anti-PD-1 antibodies, n [%] | |
| Toripalimab | 17 [47.2] |
| Pembrolizumab | 13 [36.1] |
| Tislelizumab | 6 [16.7] |
*The Child–Pugh score was 7
IQR Interquartile range, ECOG Eastern Cooperative Oncology Group, CA19-9 carbohydrate antigen 19–9, HBV hepatitis type B virus, and TNM tumor node metastasis classification